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Abstract  
 
Background and Aims: Community pharmacies have a central role in the provision of Opiate Substitution 
Therapy (OST) for drug misusers, offering accessible, additional health services within recovery-oriented 
systems of care.   
 
However, little is known about the patients receiving OST, availability and uptake of related services and 
associated pharmacy characteristics.  
 
We aimed to describe OST in terms of patients, pharmacies and services within the United Kingdom’s largest 
health authority, NHS Greater Glasgow and Clyde, Scotland. 
 
Methods: Patients completed semi-structured questionnaires and pharmacists provided summary statistics 
relating to OST provision.  
 
Results: Responses from 508 patients receiving OST from 111 participating pharmacies revealed an established 
patient population, with 89% (449/507) aged 30 years or above and 80% (387/484) attending the same 
pharmacy for 1 year or more. Methadone was the main form of OST (96% (487/508), with 97% (491/504) 
receiving supervision. 
 
Within pharmacies, OST consumption was supervised in one of four main areas: consultation room, dispensing 
hatch, quiet/private area or over the counter.  Location of supervision was considered suitably private by 96% of 
patients. Positive staff attitudes, privacy and the provision of additional health services were key factors 
influencing choice of pharmacy.  
 
Additional health services were offered to 75% of patients and included information provision (43%), 
signposting to other health-care providers (72%) and a Scottish service offering free advice and medicines for 
minor ailments (74%).   
 
Conclusion: Patients and pharmacists have developed working relationships, enabling  access to multiple 
services associated with health gain and harm reduction. Further development of enhanced services in 
community pharmacies is merited.  
 
Keywords: Methadone; OST; Community Pharmacy. 
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INTRODUCTION  1 
Opiate Substitution Therapy (OST) is a successful and cost-effective treatment for opioid dependence (Maas et 2 
al. 2013; Mattick et al. 2009).  Receiving OST reduces morbidity and mortality (Kimber et al. 2010) in 3 
individuals dependent on illicit opiates.  Methadone-related deaths reduced four-fold following the introduction 4 
of supervised consumption in community pharmacies in Scotland and England (Strang et al. 2010), and 5 
supervision of OST is recommended for a minimum period of three months (Department of Health (England 6 
(DOH) and the Devolved Administrations 2007; National Institute for Health and Care Excellence (NICE) 7 
2007; Royal College of General Practicioners (RCGP) 2011).  Community pharmacies play a central role in the 8 
provision of OST, with many offering dispensing and supervised consumption within a convenient (Anstice et 9 
al. 2009; Luger et al. 2000; Mackridge et al. 2010) and discreet location (Mackridge et al. 2010).  Current 10 
United Kingdom prescribing guidelines recommend supervised consumption in the interest of public safety 11 
(DOH 2007). Supervised methadone consumption was introduced over 10 years ago (Roberts et al. 1997). 12 
Prescribers use their professional judgement to relax the requirement for daily supervision, e.g. if the home 13 
environment is suitable for safe storage and daily supervision restricts recovery.  14 
 15 
OST is widely accepted by patients and the general public as part of community pharmacy provision (Lawrie et 16 
al. 2003, Lawrie et al. 2004), and community pharmacies are viewed as important primary care providers. 17 
Within their recommendations to the Scottish Government, the Scottish Drug Strategy Delivery Commission 18 
(SDSDC) recommended the development of a national specification for pharmacy services for people who use 19 
drugs, expanding pharmacists’ roles to contribute to a holistic recovery-oriented system of care (SDSDC 2013).  20 
Many Scottish pharmacies also provide clean injecting equipment for people who inject drugs, creating an 21 
important role for the community pharmacist as a point of contact (Roberts and Hunter 2004). 22 
 23 
There are an estimated 59,500 illicit drug users in Scotland, of whom 31.8% access services within NHS Greater 24 
Glasgow & Clyde (NHS GGC) (Information Services Division (ISD) 2014).  It is estimated that 22,000 25 
individuals are in receipt of methadone in Scotland (Scottish Government 2008); within NHS GGC, 26 
approximately 8,000 individuals are prescribed methadone and 1,000 prescribed buprenorphine/naloxone. The 27 
majority of community pharmacies (Audit Scotland 2012) and users of OST services (SDSDC 2013) are based 28 
in areas of high socio-economic deprivation.  Almost 80% of community pharmacies provide supervision of 29 
OST and engage with patients receiving OST on a daily basis (Scottish Government 2008).   30 
Previous research has focused on the practice and attitude of community pharmacists and prescribers and the 31 
experience of patients in relation to OST dispensing and supervision, predominantly methadone (Table 1).  32 
Given the lack of contemporary information about the patients receiving and pharmacies providing OST and 33 
related services, together with the need for better evidence to inform continuous quality improvement (Bloor 34 
2007; Scottish Government 2008; SDSDC 2013), we sought to characterise patients, pharmacies and services in 35 
terms of OST in the UK’s largest health board, Greater Glasgow and Clyde.  36 
 37 
 38 
METHODS  39 
 4 
Greater Glasgow and Clyde is located in the West of Scotland and covers a population of 1.1 million.  Two 1 
hundred and ninety two community pharmacies (for profit organisations contracted to act on behalf of the NHS 2 
in relation to specified services, e.g. OST provision, prescription dispensing and advice) were invited to 3 
participate.  One hundred and eleven (38%) pharmacies agreed.  Ethical approval was not required. 4 
 5 
Development of questionnaire 6 
A semi-structured patient questionnaire (Appendix 1) was developed by AL and CH, then reviewed for face and 7 
content validity before inviting comment from a group of 15 patients who were receiving OST. The final 8 
version consisted of 27 questions pertaining to: demographics; arrangements for OST provision in the 9 
pharmacy; information, advice and signposting; relationships with pharmacy staff; and overall service provision 10 
(Appendix 1).   11 
 12 
Distribution and analysis of questionnaire 13 
Questionnaires were disseminated during September to November 2010. In each pharmacy, staff were asked to 14 
distribute questionnaires to patients receiving OST.  All questionnaire responses were anonymised.  15 
 16 
Completed questionnaires were entered onto an Excel spreadsheet (Microsoft Office 2007), cross checked for 17 
accuracy and completeness and analysed using basic descriptive statistics. 18 
 19 
 20 
RESULTS  21 
Thirty (27%) of pharmacies returned between one and three questionnaires; 65(58%) returned 4-6 and 16(15%) 22 
returned between seven and ten questionnaires. Respondents’ demographic details were comparable with all 23 
patients receiving OST in NHS GGC in terms of gender (66% male respondents vs. 68% male within NHS 24 
GGC), and age group (85.1% of  respondents 30-49 years vs. 81.2% in NHS GGC). 25 
 26 
 27 
Pharmacy characteristics 28 
The characteristics of participating community pharmacies are given in Table 2. Reflecting the NHS GGC 29 
locality, 87% of pharmacies served large urban areas.  Pharmacy ownership suggested a diverse range of all 30 
possible categories: part of large multiple chain (40%); independently owned (39%); small multiple (16%) or 31 
based within a health centre (5%). The majority (77%) of participating pharmacies were located in Scotland’s 32 
most socioeconomically deprived areas.  33 
 34 
Approximately one quarter of pharmacies were providers of injecting equipment, e.g. needles, syringes and 35 
other paraphernalia.  Over half (56%) of pharmacies provided OST to more than 30 patients, including 21% who 36 
supplied OST for over 60 patients.  Methadone constituted the main form of OST supplied in pharmacies (Table 37 
2).  All pharmacies offered a supervised consumption service for methadone and alternative OST.   38 
 39 
Patient characteristics 40 
 5 
Table 3 provides patients’ summary characteristics, classified by type of OST (methadone or alternative OST).  1 
Of 508 patients, 483 (95%) received methadone only and 4 (0.8%) received concomitant disulfiram (for 2 
maintenance of alcohol abstinence). Twenty one patients (4%) received alternative OST (buprenorphine or 3 
combined buprenorphine/naloxone (Suboxone®)) and are described separately.  The majority of patients 4 
receiving methadone (53%) were in the 30-39 year age band while over one third were 40 years or older. Most 5 
patients receiving alternative OST were 40-49 years old. For each type of OST, the ratio of male to female was 6 
two to one.   7 
 8 
Within each category of OST, the majority of patients (87% methadone, 76% alternative OST) lived in rented 9 
accommodation.  Similar proportions of patients were homeless or roofless (total 6%) as owned their own 10 
property (total 7%).  11 
 12 
While most patients had attended the same pharmacy for less than six years, a substantial minority (94/508; 13 
18%) had attended the same pharmacy for over 7 years.  14 
 15 
Treatment and supervision arrangements 16 
Treatment and supervision arrangements are described in Table 4.  The majority (97%) of patients received 17 
supervised OST; in most cases, pharmacies supervised on 5 or more days per week. The location of supervision 18 
in pharmacies varied, with the greatest proportion (42%) supervised in a private consultation room. Other 19 
arrangements included the use of a dispensing hatch (27%) and a quiet/private area (21%).  The perceived 20 
suitability of each location varied, with 206/207 (99.5%) of those using consultation rooms disclosing that they 21 
felt the room was suitably private, while 30/34 (88%) of those who consumed their OST at the open counter 22 
regarded this arrangement as suitable.  23 
 24 
Approximately half of respondents declared that their pharmacies had restrictions on OST supervision or 25 
collection times. Eighty percent of participants receiving methadone and 95% of those receiving alternative OST 26 
reported that they waited for five minutes or less.  27 
 28 
Reasons for choosing a pharmacy for OST 29 
Receiving healthcare advice was highly ranked (Figure 1) as an important factor in choosing a pharmacy: 36% 30 
of participants stated that it was a factor in their decision, although it was perceived to be less important than 31 
staff attitude (82%), privacy (71%), proximity to home (67%) and waiting times (59%).  32 
 33 
Additional services 34 
Additional health information was reportedly received by 75% of patients (Table 5). Information provision 35 
extended to a wide range of related topics: safe storage of medicine in the home (43%); role of medicine (24%); 36 
overdose risk (22%); anthrax (20%); hepatitis (20%) and alcohol (19%). Verbal exchange of information was 37 
the most commonly preferred method (64% of patients).  38 
 39 
 6 
Other services that were utilised included: purchase of over the counter medicine (51%); prescription collection 1 
service (30%) and a needle exchange service (26%). Most participants were aware of the Minor Ailment Service 2 
(MAS: a free service enabling community pharmacists to advise, supply products free of charge or refer patients 3 
and their families presenting with minor health concerns), with almost three-quarters (74%) registered with their 4 
community pharmacy for the MAS in addition to their OST provision.  5 
 6 
Seventy two percent of patients reported having been signposted to attend other health care services.  7 
 8 
Relationship with pharmacy staff 9 
Relationships with pharmacists and dispensing staff were positive (Table 6), with over 70% of patients reporting 10 
“excellent” relations with pharmacists, pharmacy staff, and counter assistants.   11 
 12 
 13 
DISCUSSION  14 
 15 
Principal findings 16 
Our results indicate that pharmacies with a range of ownership categories, located in areas of deprivation, 17 
supervise a full range of opiate substitution therapies.  Patients receiving OST access a variety of associated 18 
services and wider health improvement interventions through their community pharmacy. Community 19 
pharmacies, more than half of which supervise supplies for over 30 patients per day, six or seven days per week, 20 
had long-standing relationships with the same patients for prolonged spells of recovery, sometimes lasting more 21 
than 10 years.  This context offers an encouraging, stable and supportive environment in which individual OST 22 
patients may find it easier to recover from substance misuse. 23 
 24 
While we did not design the study to test for statistically significant differences, patients receiving alternative 25 
OST appeared to be older than those receiving methadone.  It is possible that this may reflect the fact that 26 
buprenorphine-containing products are a newer treatment option and patients who have been previously 27 
prescribed methadone may have switched following treatment failure with methadone. Patients were 28 
predominately receiving methadone, which has been available as an OST for a longer period of time. If our 29 
sample can be considered representative, our results show, for the first time, an older population of patients in 30 
recovery for a longer period of time, using the same community pharmacy. This finding, together with 31 
developments in pharmacist independent prescribing, provides a platform for additional clinical service 32 
provision aiming to retain patients in treatment and maximise recovery.   33 
Arrangements for consumption of OST were reported as suitable, even within the small group of patients who 34 
used the open counter, in full visibility of other customers and staff. Restrictions in the times of supply were not 35 
found to be problematic. This is potentially linked to the positive reports that patients had relatively short 36 
waiting times within the pharmacy.  37 
 38 
Appraisal of methods 39 
 7 
We involved a larger number of pharmacies and patients than previous work. As pharmacies in Glasgow were 1 
the first to provide supervised OST, this may have led to relatively earlier innovation and service expansion than 2 
occurred in other health localities. Pharmacists and patients were self-selecting, which may limit the 3 
generalisability of our findings. Given the requirement for patients to return responses to pharmacy staff, 4 
respondents may have been more likely to have favourable views on the services through a social desirability 5 
effect. Literacy among people taking OST is thought to be poorer than average (NHS Health Scotland 2009; 6 
Scottish Drugs Forum (SDF) 2007), raising the possibility that those who were less able to read, understand and 7 
respond, may have been less likely to participate. Eighty seven percent of our participating pharmacies were 8 
located in large urban areas (defined as settlements of over 125,000 people), with the remainder located in other 9 
urban areas or accessible small towns (ISD – need to reference and please also reference footnote of table 2 if 10 
we have not already done so). While we have not analysed our data by pharmacy location, our findings, while 11 
applicable to urban areas and accessible small towns, may be generalisable to rural areas, where attitudes of 12 
pharmacists towards drug misusers and service provision, are not significantly different (Matheson et al. 2007).  13 
Further work is required to test whether these or other potential explanatory variables, e.g. patient 14 
demographics, independently predict retention in OST, or other outcomes of interest. We did not collect data on 15 
prescribing of psychotropic drugs, or other co-morbidities, which limits a broader understanding of the typology 16 
of the patients included.  17 
 18 
Comparison with previous work 19 
There are reports of higher rates of drug-related deaths associated with lower rates of supervision (Bloor 2007; 20 
Seymour et al. 2003; Strang et al. 2010). We found a higher rate of supervised supply for both methadone (98%) 21 
and alternative OST (95%) than in previous studies of pharmacist-reported supervision (Matheson et al. 2007). 22 
The higher rates of supervision are due local prescribing guidance within the integrated addiction services in 23 
NHS GGC.  In NHS GGC, 96% of community pharmacies offer the opportunity to dispense and supervise OST, 24 
as part of a commitment to patient care and harm reduction strategies, thereby ensuring that there is availablility 25 
of places for community pharmacy-based OST.  In addition, it would appear that patients are accepting of high 26 
levels of supervision. Supervision is perhaps more acceptable when other factors, such as the attitude of 27 
pharmacy staff or the availability of a suitably private area to consume OST, are perceived favourably by 28 
patients. Patients consuming methadone in highly visible areas are known to feel embarrassed by exposure to 29 
other customers and pharmacy staff (Anstice et al. 2009; Bloor 2007; Luger et al. 2000).  Given that 12% of 30 
those consuming OST over the counter found the arrangement unsuitable, yet persisted with this arrangement, it 31 
is possible that the advantages of using their chosen pharmacy, e.g. short waiting times or positive staff 32 
attitudes, outweighed any disadvantages. If this is the case, our findings uncover features that could be the focus 33 
of quality improvement, for pharmacy and other services involved in OST.  34 
 35 
Some pharmacies have restrictions on the times when patients receiving OST can attend, usually in an attempt 36 
to structure workflow amidst other competing priorities. From a patient’s perspective, these restrictions may 37 
seem inflexible and hamper efforts to return to, or establish employment, education and family life (Bloor 38 
2007). We report that most patients acknowledged minor restrictions, but by design, we did not explore the 39 
 8 
impact or importance of this finding. However, we ascertained that the vast majority of patients waited less than 1 
six minutes for their OST, which is important to patients (Deering et al. 2011). 2 
 3 
Addressing the wider health care needs of people receiving OST is challenging. OST is one aspect of harm 4 
reduction, and should be set within the context of a recovery programme involving multiple services from health 5 
and social care. Pharmacy-based services for patients receiving OST are an important component of recovery 6 
services. The high reported uptake of additional and associated services is noteworthy in a population where 7 
provision has been historically low (Matheson et al. 1999). Our findings may indicate a shift over time in 8 
pharmacy OST provision, from initial low levels of provision, through increased awareness of opportunities for 9 
health improvement (Mackridge et al. 2010), to recommendations for the provision of associated pharmaceutical 10 
services (SDSDC 2013), in parallel with recovery-focused treatment (Scottish Government 2008).  There is 11 
evidence from repeated surveys, of positive trends in pharmacists’ attitudes over time towards providing 12 
services to people using drugs (Chief Scientist Office (CSO) 2014). In demonstrating provision and utilisation 13 
of pharmacy-based health promotion and harm reduction activities on a wide scale, our results suggest that 14 
pharmacists may have translated improved attitudes into improved practice. This is encouraging, given the 15 
emphasis that patients place on staff attitudes. The positive relationships observed between pharmacist and 16 
patient may be relevant to both the offering (Luger et al. 2000) and the accessing of additional services 17 
(Matheson et al. 2007) and, we would expect, to recovery more broadly. 18 
 19 
Clinical and scientific implications  20 
These findings extend our understanding of the positive contribution pharmacists are making to various aspects 21 
of healthcare for patients receiving OST. Given the length and strength of the pharmacist-patient relationship, 22 
there is an obvious platform for the introduction of additional targeted services by pharmacists for this patient 23 
group. There is an increased prevalence of older drug users within Scotland and as this population ages, there 24 
will be challenges in relation to managing multiple medications, and drug-related or other morbidities.  Drug-25 
related deaths among older drug users are more prevalent, and the number of hospital admissions for this patient 26 
population increases due to medical and psychiatric morbidities (Information Services Division 2015). Older 27 
drug users tend to generally have poorer physical and mental health (Roe 2010; Roe et al. 2010; Scottish Drugs 28 
Forum (SDF) 2009).  Therapeutic relationships should foster greater engagement with other health services and 29 
health interventions.  Community pharmacies could be involved in overdose awareness and naloxone supply 30 
(Green et al. 2015; Scottish Government 2014), blood borne virus testing (Scottish Government 2011) and 31 
supply of direct acting anti-viral Hepatitis C treatment, as well as providing services to manage long term 32 
medical conditions such as the Chronic Medication Service (CMS) in Scotland (Scottish Government 2009). 33 
While our descriptive study, by design, did not seek to examine the impact of pharmacy-based OST on 34 
dimensions such as social adjustment, health improvement, or criminal behaviour, other available evidence 35 
indicates a positive impact of treatment retention on these outcomes (Palmateer et al 2014, Scottish Government 36 
Social Research 2009).  37 
 38 
 39 
 40 
 9 
Further work 1 
This study has indicated the extent of provision and uptake of pharmacist-led activities for patients receiving 2 
OST, and can be used as a platform to test more advanced services in this population e.g. blood borne virus 3 
testing, independent prescribing, as part of a collaborative approach for an ageing population of drug users.  4 
Longitudinal follow-up in the context of experimental or analytical studies is needed to examine whether 5 
pharmacy service delivery promotes retention in treatment and whether it has an independent contribution to 6 
improving health outcomes, e.g. prevention of blood borne diseases, social adjustment or minimising criminal 7 
behaviour. Future work could include health service contacts and consider cost effectiveness of pharmacy-based 8 
OST services in this context. 9 
 10 
CONCLUSIONS  11 
Urban patients receiving OST in NHS Greater Glasgow and Clyde access a wide range of services offered by 12 
community pharmacies, both in relation to addiction-specific interventions and general health interventions.  13 
Patient and pharmacy characteristics point to the need and potential for further role expansion for community 14 
pharmacies.  The long-standing and positive relationships between patients and pharmacy staff are of particular 15 
importance within the context of an ageing population of drug users engaging in daily treatment in pharmacies.  16 
 17 
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Figure 1 Reasons for choosing a pharmacy 16 
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Table 1 Comparison of Relevant Studies  
 
 
 
Authors Laird et al 
(current study) 
Anstice et al 
2009 
Bloor 2007 Britton and 
Scott 2006 
Holland et 
al. 2012 
Luger et al. 
2000 
Madden at 
al. 2008 
Matheson et 
al. 2007 
Neale 1998 Notley et al. 
2014 
Sheridan et 
al. 2007 
Winstock et al. 
2008 
Date of 
Publication 
2015 2009 2007 2006 2012 2000 2008 2007 1998 2014 2007 2008 
Country of 
Origin 
Scotland Canada England England Scotland England Australia Scotland Scotland England England Australia 
Methods Questionnaire Interviews Mixed 
methods 
Questionnaire RCT pilot Mixed 
methods 
Questionnaire Postal 
Questionnaire 
Interviews Qualitative 
interviews 
Questionnaire Questionnaire 
Number of 
pharmacies 
111  106 707  17  789 22 8 2349 50 
Number of 
OST patients 
508 64 350 0 60 79 432 0 80 293  508 
Location of 
supervision 
Community 
pharmacies  
Public health 
units (n = 2), 
AIDS 
service 
organisations 
(n = 2) 
Community 
pharmacies  
Community 
pharmacies 
Community 
pharmacies 
Community 
pharmacies  
Clinics (n = 
9) 
Community 
pharmacies  
Community 
pharmacies 
Community 
pharmacies 
Community 
pharmacies 
Community 
pharmacies 
Outcomes 
Assessed 
Characterisation of 
patients, 
pharmacies and 
services in terms 
of OST. 
Patients’ 
experiences 
of 
supervised 
methadone 
consumption 
Service 
providers’ 
practice of 
and attitude 
to Methadone 
prescribing; 
Patients’ 
opinions and 
experiences 
of supervised 
methadone 
consumption  
Service 
providers’ 
practice of 
OST 
provision and 
health 
promotion 
activities 
related to 
drug use 
Pilot 
feasibility 
study of 
RCT of 3 
supervision 
models to 
measure 
treatment 
retention 
and illicit 
heroin use. 
Service 
providers’ 
and patients’ 
perceptions 
of the 
feasibility 
and 
acceptability 
of 
supervised 
methadone 
consumption 
services 
Patients’ 
experiences 
of OST 
provision 
Service 
providers’ 
practice of 
and attitude 
to OST 
provision 
Patients’ 
experiences 
and 
opinions of 
prescribed 
methadone 
treatment 
Patient 
retention in 
treatment. 
Exploration 
of patient and 
professional 
views and 
experiences 
of supervised 
consumption. 
Pharmacists’ 
attitudes 
towards 
service 
provision and 
novel 
services 
Patients’ 
experiences of 
health problems 
related to OST 
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Table 2 Pharmacy level summary characteristics  1 
Pharmacy Characteristic Pharmacies (n = 111) 
Urban/Rural Classification
a,b 
Large Urban Area 
Other Urban Area 
Accessible Small Towns 
 
96 (87%) 
12 (11%) 
2 (2%) 
Pharmacy ownership
b 
Independent 
Small multiple 
Large multiple 
Health centre 
 
43 (39%) 
18 (16%) 
44 (40%) 
5 (5%) 
Location (Level of Socioeconomic Deprivation)
b 
1 (Most Deprived) 
2 
3 
4 
5 (Least Deprived) 
 
60 (55%) 
24 (22%) 
7 (6%) 
11 (10%) 
8 (7%) 
Injecting Equipment Provider
c 28 (26%) 
Number of patients receiving OST
d 
1 - 30 
31 – 60 
> 60 
 
47 (44%) 
37 (35%) 
22 (21%) 
Type of Medication 
Methadone or Methadone + Disulfiram 
Buprenorphine or Buprenorphine + Naloxone 
 
93 (84%) 
18 (16%) 
a ISD Classification (ISD 2010)   Missing data: b n = 1 pharmacy; c n = 2 pharmacies; d n = 5 pharmacies. 2 
  3 
 4 
5 
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Table 3 Characteristics of participants receiving methadone or alternative OST  1 
Participant characteristic Methadone
a 
Patients 
n = 487 (96%) 
Alternative OST
b 
Patients 
n = 21 (4%) 
Age (years)
c 
20-29 
30-39 
40-49 
>50 
 
54 (11%) 
258 (53%) 
160 (33%) 
14 (3%) 
 
4 (19%) 
3 (14%) 
11 (52%) 
3 (14%) 
Gender 
Male 
Female 
 
324 (66%) 
163 (34%) 
 
13 (62%) 
8 (38%) 
Housing Status
d,e 
Owned  
Rented 
Homeless (in accommodation) 
Sleeping rough/Roofless 
 
31 (6%) 
423 (87%) 
5 (1%) 
27 (6%) 
 
2 (10%) 
16 (76%) 
 
2 (10%) 
Duration of Attendance at Current Pharmacy
f 
<1year 
1 to 3 years 
4 to 6 years 
7 to 9 years 
≥10 years 
 
91 (20%) 
180 (39%) 
101 (22%) 
37 (8%) 
54 (12%) 
 
6 (29%) 
9 (43%) 
3 (14%) 
1 (5%) 
2 (9%) 
a Comprises 483 participants receiving Methadone and 4 participants receiving Methadone with concomitant 2 
Disulfiram 3 
b Comprises 1 participant receiving Buprenorphine and 20 participants receiving Buprenorphine/Naloxone 4 
combination. 5 
Missing data: c n = 1 Methadone; d n = 1 Methadone; e n = 1 Alternative OST; f  n = 24 Methadone. 6 
7 
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Table 4 Patient reported treatment and supervision arrangements 1 
 2 
Arrangement Methadone Patients 
(n = 487) 
Alternative OST 
Patients 
(n = 21) 
Supervised Supply
a
 
Yes 
No 
 
471 (98%) 
12 (2%) 
 
20 (95%) 
1 (5%) 
Frequency of Supervision
b,c
 
6 or 7 days/week  
5 days/week 
3 days/week 
2 days/week 
1 day/week 
 
256 (54%) 
183 (39%) 
13 (3%) 
11 (2%) 
10 (2%) 
 
14 (70%) 
3 (15%) 
1 (5%) 
1 (5%) 
1 (5%) 
Location of Supervision
d 
Consultation room only 
Consultation Room + Other 
Dispensing hatch only 
Dispensing hatch + Other 
Quiet/Private area only 
Counter only 
Unspecified 
 
204 (42%) 
5 (1%) 
124 (25%) 
5 (1%) 
105 (22%) 
31 (6%) 
13 (3%) 
 
3 (14%) 
1 (5%) 
10 (48%) 
 
3 (14%) 
3 (14%) 
1 (5%) 
Location of Supervision Perceived as Suitable
e
 
Consultation Roomf 
Dispensing Hatch 
Quiet/Private Area 
Counterg 
 
186/196 (95%) 
121/124 (98%) 
104/105 (99%) 
24/28 (86%) 
 
3/3 (100%) 
9/10 (90%) 
3/3 (100%) 
3/3(100%) 
Perceived Time Restrictions for Medication Collection
h,i 
Yes 
No 
 
266 (57%) 
202 (43%) 
 
10 (50%) 
10 (50%) 
Reported average waiting times
j 
0-5 minutes 
6-10 minutes 
11-15 minutes 
16-20 minutes 
>25 minutes 
 
386 (80%) 
76 (16%) 
12 (2%) 
7 (1%) 
4 (1%) 
 
20 (95%) 
1 (5%) 
 
Takeaway Doses Supplied in Individual Bottles for Each 
Day
k,l 
Yes 
No 
 
 
445 (93%) 
35 (7%) 
 
 
7 (37%) 
12 (63%) 
d 11 participants reported more than one location.   3 
e For those reporting only one place of supervision (n = 483). 4 
Missing data: a n = 4 Methadone; b n = 14 Methadone; c n =1 Alternative OST; f n = 8 Methadone; g n = 3 5 
Methadone; h n = 19 Methadone; i n = 1 Alternative OST; j n = 2 Methadone; k n = 7 Methadone; l n = 2 6 
Alternative OST. 7 
8 
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Table 5 Information, advice and signposting  1 
 2 
Information or Service Methadone Patients 
(n = 487) 
Alternative OST 
Patients 
(n = 21) 
Accessed Information on Health Matters
a 
Yes 
No 
 
356 (75%) 
118 (25%) 
 
14 (67%) 
7 (33%) 
Information Received/Accessed
b 
Safe Storage 
Smoking Cessation 
Overdose Risk 
Role of Medicine 
Hepatitis 
Anthrax 
Alcohol 
Safer Injecting 
Injection Site Wounds 
Diet 
Dental Advice 
Sexual Health 
Naloxone 
Morning-after Pill 
 
210 (43%) 
173 (36%) 
106 (22%) 
118 (24%) 
100 (21%) 
99 (20%) 
91 (19%) 
79 (16%) 
48 (10%) 
51 (10%) 
43 (9%) 
40 (8%) 
34 (7%) 
27 (6%) 
 
9 (43%) 
9 (43%) 
5 (24%) 
4 (19%) 
3 (14%) 
3 (14%) 
3 (14%) 
3 (14%) 
20 (95%) 
1 (5%) 
1 (5%) 
4 (19%) 
2 (10%) 
1 (5%) 
Preferred Method of Receiving Information
c
 
Verbal 
Leaflet 
Poster 
Text 
Email 
 
313 (64%) 
235 (48%) 
65 (13%) 
47 (10%) 
23 (5%) 
 
14 (67%) 
8 (38%) 
3 (14%) 
2 (10%) 
2 (10%) 
Type of Services Used 
Purchase Over the Counter Medicines 
Prescription Collect/Delivery Service 
Needle Exchange 
Smoking Cessation 
Condom Provision 
Morning-after Pill 
Alcohol Brief Interventions 
 
251 (52%) 
149 (31%) 
131 (27%) 
116 (24%) 
22 (5%) 
26 (5%) 
13 (3%) 
 
10 (48%) 
5 (24%) 
2(10%) 
6 (29%) 
1 (5%) 
 
 
Aware of Minor Ailments Service
d 
Yes 
No 
 
420 (88%) 
57 (12%) 
 
16 (76%) 
5 (24%) 
Registered for Minor Ailments Service
e,f 
Yes 
No 
 
346 (74%) 
121 (26%) 
 
14 (70%) 
6 (30%) 
Signposted by Pharmacist 
GP/Practice Nurse 
Addiction Team 
Hospital  
Dentist 
Sexual Health Clinic 
None 
 
161 (33%) 
78 (16%) 
64 (13%) 
44 (9%) 
6 (1%) 
247 (51%) 
 
8 (38%) 
1 (5%) 
1 (5%) 
1 (5%) 
 
12 (57%) 
b Participants may have received/accessed more than one topic of information; 6 participants reported 3 
receiving/accessing all topics of information. 4 
c 7 participants (6 Methadone, 1 Alternative OST) reported a preference for all types of communication; 22 5 
participants (21 Methadone, 1 Alternative OST) reported no preference. 6 
Missing data: a n = 13 Methadone; d n = 10 Methadone; e n = 20 Methadone; f n = 1 Alternative OST.7 
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Table 6 Patient reported relationships with pharmacy staff 1 
 2 
Relationship Methadone Patients 
(n = 487) 
Alternative OST 
Patients 
(n = 21) 
Relationship with Pharmacist
a 
Excellent 
Good 
Poor 
Very Poor 
 
347 (72%) 
132 (27%) 
1 (0.2%) 
2 (0.4%) 
 
17 (81%) 
4 (19%) 
Relationship with Pharmacy Staff
b 
Excellent 
Good 
Poor 
Very Poor 
 
354 (75%) 
114 (24%) 
1 (0.2%) 
2 (0.4%) 
 
19 (90%) 
2 (10%) 
Relationship with Counter Staff
c 
Excellent 
Good 
Poor 
Very Poor 
 
348 (74%) 
116 (25%) 
1 (0.2%) 
3 (0.6%) 
 
19 (90%) 
2 (10%) 
 3 
Missing Data: a n= 5 Methadone; b n = 16 Methadone; c n = 19 Methadone 4 
